Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment

Jonathan Underwood, Davide De Francesco, Robert Leech, Caroline A Sabin, Alan Winston, Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study, Jonathan Underwood, Davide De Francesco, Robert Leech, Caroline A Sabin, Alan Winston, Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study

Abstract

Objective: The reported prevalence of cognitive impairment remains similar to that reported in the pre-antiretroviral therapy era. This may be partially artefactual due to the methods used to diagnose impairment. In this study, we evaluated the diagnostic performance of the HIV-associated neurocognitive disorder (Frascati criteria) and global deficit score (GDS) methods in comparison to a new, multivariate method of diagnosis.

Methods: Using a simulated 'normative' dataset informed by real-world cognitive data from the observational Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) cohort study, we evaluated the apparent prevalence of cognitive impairment using the Frascati and GDS definitions, as well as a novel multivariate method based on the Mahalanobis distance. We then quantified the diagnostic properties (including positive and negative predictive values and accuracy) of each method, using bootstrapping with 10,000 replicates, with a separate 'test' dataset to which a pre-defined proportion of 'impaired' individuals had been added.

Results: The simulated normative dataset demonstrated that up to ~26% of a normative control population would be diagnosed with cognitive impairment with the Frascati criteria and ~20% with the GDS. In contrast, the multivariate Mahalanobis distance method identified impairment in ~5%. Using the test dataset, diagnostic accuracy [95% confidence intervals] and positive predictive value (PPV) was best for the multivariate method vs. Frascati and GDS (accuracy: 92.8% [90.3-95.2%] vs. 76.1% [72.1-80.0%] and 80.6% [76.6-84.5%] respectively; PPV: 61.2% [48.3-72.2%] vs. 29.4% [22.2-36.8%] and 33.9% [25.6-42.3%] respectively). Increasing the a priori false positive rate for the multivariate Mahalanobis distance method from 5% to 15% resulted in an increase in sensitivity from 77.4% (64.5-89.4%) to 92.2% (83.3-100%) at a cost of specificity from 94.5% (92.8-95.2%) to 85.0% (81.2-88.5%).

Conclusion: Our simulations suggest that the commonly used diagnostic criteria of HIV-associated cognitive impairment label a significant proportion of a normative reference population as cognitively impaired, which will likely lead to a substantial over-estimate of the true proportion in a study population, due to their lower than expected specificity. These findings have important implications for clinical research regarding cognitive health in people living with HIV. More accurate methods of diagnosis should be implemented, with multivariate techniques offering a promising solution.

Conflict of interest statement

Competing Interests: The POPPY study is funded from investigator initiated grants from BMS, Gilead Sciences, Janssen, Merck and ViiV Healthcare to Imperial College London on behalf of Professors Alan Winston and Caroline Sabin. Alan Winston is a member of the PLOS ONE editorial board. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1. Convergence of the critical value…
Fig 1. Convergence of the critical value to determine cognitive impairment as the sample size increases.
This model assumes a six test/domain model. The critical value from simulated data was the mean of 100 replicates.
Fig 2. Comparison of the cognitive domain…
Fig 2. Comparison of the cognitive domain correlation matrices for the HIV-positive and HIV-negative control groups from the POPPY study.
Visualisation of the inter-domain correlation matrices for the HIV-negative (panel a) and HIV-positive (panel b) participants of the POPPY study. Colour scale determined by Pearson’s r (scale to the right of the figure).
Fig 3. Histograms of a simulated study…
Fig 3. Histograms of a simulated study population with a 10% prevalence of cognitive impairment.
Panel a) 90% of the population are ‘normal’ and have a mean (standard deviation) T-score of 50 (10)–red. 10% of the population are impaired and have a mean T-score of 30 (10). Panels b-d: how the population is labelled by method used to define impairment.
Fig 4. Positive predictive value of each…
Fig 4. Positive predictive value of each diagnostic method by prevalence of impairment in the simulated study population.

References

    1. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21: 1915–1921. doi:
    1. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. American Academy of Neurology; 2010;75: 2087–2096. doi:
    1. Su T, Schouten J, Geurtsen GJ, Wit FW, Stolte IG, Prins M, et al. Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection. AIDS. 2015;29: 547–557. doi:
    1. McDonnell J, Haddow L, Daskalopoulou M, Lampe F, Speakman A, Gilson R, et al. Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. J Acquir Immune Defic Syndr. 2014;67: 120–127. doi:
    1. De Francesco D, Underwood J, Post FA, Vera JH, Williams I, Boffito M, et al. Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis. 2016;16: 617 doi:
    1. Underwood J, De Francesco D, Post FA, Vera JH, Williams I, Boffito M, et al. Associations between cognitive impairment and patient‐reported measures of physical/mental functioning in older people living with HIV. HIV Med. 2016;29: 547 doi:
    1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: 1789–1799. doi:
    1. Spearman C. “General Intelligence,” Objectively Determined and Measured. The American Journal of Psychology. 1904;15: 201 doi:
    1. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis. 2011;11: 356 doi:
    1. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26: 307–319. doi:
    1. Huizenga HM, Smeding H, Grasman RPPP, Schmand B. Multivariate normative comparisons. Neuropsychologia. 2007;45: 2534–2542. doi:
    1. De Maesschalck R, Jouan-Rimbaud D, Massart DL. The Mahalanobis distance. Chemometrics and Intelligent Laboratory Systems. 2000;50: 1–18.
    1. Overton ET, Kauwe JSK, Paul R, Tashima K, Tate DF, Pathai S, et al. Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav. 2011;15: 1902–1909. doi:
    1. Cysique LAJ, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21: 185–194. doi:
    1. Steiger JH. Testing Pattern Hypotheses On Correlation Matrices: Alternative Statistics And Some Empirical Results. Multivariate Behav Res. 1980;15: 335–352. doi:
    1. Venables WN, Ripley BD. Modern applied statistics with S 4 edition Springer; New York; 2002.
    1. Hanninen T, Koivisto K, Reinikainen KJ, Helkala EL, Soininen H, Mykkänen L, et al. Prevalence of ageing-associated cognitive decline in an elderly population. Age Ageing. 1996;25: 201–205.
    1. Taylor MJ, Heaton RK. Sensitivity and specificity of WAIS–III/WMS–III demographically corrected factor scores in neuropsychological assessment. Journal of the International Neuropsychological Society. Cambridge University Press; 7: 867–874.
    1. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332: 1080 doi:
    1. Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82: 2055–2062. doi:
    1. Cole MA, Margolick JB, Cox C, Li X, Selnes OA, Martin EM, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007;69: 2213–2220. doi:
    1. Heaton RK, Franklin DR, Deutsch R, Letendre S, Ellis RJ, Casaletto K, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. CLIN INFECT DIS. 2015;60: 473–480. doi:
    1. Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2015. doi:

Source: PubMed

3
Předplatit